Stop the DIY Search: An Inadequate Drug Patent FTO Opinion Puts You at Risk of Willful Infringement
Courts can triple damages for willful infringement. A flawed freedom-to-operate search is not a defense — it is evidence you […]
The Real Price of a Drug: A Total Cost of Ownership Model for Pharma Procurement Teams
Unit price is the number everyone fights over. It’s also the number that matters least. Pharmaceutical procurement has a dirty
The Real Price of a Drug: A Total Cost of Ownership Model for Pharma Procurement Teams Read Post »
Drug Patent Term Extensions: How Pharma Turns Extra Time Into Billions
The Clock You Can Buy In the drug industry, time is not just money. It is the only thing that
Drug Patent Term Extensions: How Pharma Turns Extra Time Into Billions Read Post »
The Hatch-Waxman Playbook: How Generic Drugmakers Use Patent Litigation to Get to Market Early
Introduction: The Law That Reshaped American Medicine In 1984, a California congressman named Henry Waxman and a Utah senator named
How to Offer Abuse-Deterrent Reformulation Packages Before Drug Patent Loss of Exclusivity — and Win the Contract
The Problem With Waiting Most formulation vendors approach business development reactively. They wait for a drug to lose exclusivity, watch
Old Drugs, New Signals: What the Side-Effect Conversation is Really Saying
There’s a quiet shift happening in pharmacology that doesn’t show up neatly in prescribing guidelines or FDA labels. It shows
Old Drugs, New Signals: What the Side-Effect Conversation is Really Saying Read Post »
What a Drug Patent Is Really Worth: How Litigation Costs Reshape Acquisition Value
The Number Nobody Puts in the Model Every pharma M&A deal starts with a revenue forecast. Bankers build complex discounted
What a Drug Patent Is Really Worth: How Litigation Costs Reshape Acquisition Value Read Post »
Two Clocks, One Drug: How Patents and FDA Exclusivity Actually Determine When Your Drug Faces Competition
Every pharmaceutical executive knows the word “patent cliff.” Fewer can accurately define the legal machinery underneath it. Fewer still understand
Small Molecule vs. Biologic: Tailoring Your Drug Patent LOE Strategy for Generics vs. Biosimilars
Why Your LOE Strategy Depends on Molecule Type A brand-name drug losing its final patent is not one event. It
